ASX - By Stock
|
SNT |
Re:
Syntara the science explained
|
|
ma420
|
96 |
39K |
5 |
13/07/24 |
13/07/24 |
ASX - By Stock
|
96
|
39K
|
5
|
|
ASX - By Stock
|
SNT |
Re:
Syntara the science explained
|
|
ma420
|
96 |
39K |
4 |
13/07/24 |
13/07/24 |
ASX - By Stock
|
96
|
39K
|
4
|
|
ASX - By Stock
|
SNT |
Re:
SNT - General Discussions
|
|
ma420
|
117 |
32K |
14 |
13/07/24 |
13/07/24 |
ASX - By Stock
|
117
|
32K
|
14
|
|
General
|
RAC |
Re:
General Comments / Chat
|
|
ma420
|
12K |
4.2M |
10 |
13/07/24 |
13/07/24 |
General
|
12K
|
4.2M
|
10
|
|
ASX - By Stock
|
SNT |
Re:
SNT - General Discussions
|
|
ma420
|
117 |
32K |
11 |
13/07/24 |
13/07/24 |
ASX - By Stock
|
117
|
32K
|
11
|
|
ASX - By Stock
|
SNT |
Re:
SNT - General Discussions
|
|
ma420
|
117 |
32K |
5 |
12/07/24 |
12/07/24 |
ASX - By Stock
|
117
|
32K
|
5
|
|
ASX - By Stock
|
SNT |
Re:
SNT - General Discussions
|
|
ma420
|
117 |
32K |
11 |
12/07/24 |
12/07/24 |
ASX - By Stock
|
117
|
32K
|
11
|
|
ASX - By Stock
|
CU6 |
Re:
CU6 - ASX Charts
|
|
ma420
|
1.2K |
455K |
15 |
12/07/24 |
12/07/24 |
ASX - By Stock
|
1.2K
|
455K
|
15
|
|
ASX - By Stock
|
CU6 |
Re:
CU6 - ASX Charts
|
|
ma420
|
1.2K |
455K |
7 |
12/07/24 |
12/07/24 |
ASX - By Stock
|
1.2K
|
455K
|
7
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Bioshares 18th Biotech Summit Presentation
|
|
ma420
|
10 |
4.1K |
0 |
12/07/24 |
12/07/24 |
ASX - By Stock
|
10
|
4.1K
|
0
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Bioshares 18th Biotech Summit Presentation
|
|
ma420
|
10 |
4.1K |
5 |
12/07/24 |
12/07/24 |
ASX - By Stock
|
10
|
4.1K
|
5
|
|
ASX - By Stock
|
SNT |
Re:
SNT - General Discussions
|
|
ma420
|
117 |
32K |
7 |
12/07/24 |
12/07/24 |
ASX - By Stock
|
117
|
32K
|
7
|
|
ASX - By Stock
|
SNT |
Re:
SNT - General Discussions
|
|
ma420
|
117 |
32K |
7 |
12/07/24 |
12/07/24 |
ASX - By Stock
|
117
|
32K
|
7
|
|
ASX - By Stock
|
CU6 |
Re:
CU6 - Media and Industry News
|
|
ma420
|
630 |
267K |
9 |
12/07/24 |
12/07/24 |
ASX - By Stock
|
630
|
267K
|
9
|
|
ASX - By Stock
|
CU6 |
Re:
CU6 - Media and Industry News
|
|
ma420
|
630 |
267K |
6 |
12/07/24 |
12/07/24 |
ASX - By Stock
|
630
|
267K
|
6
|
|
ASX - By Stock
|
SNT |
Re:
SNT - General Discussions
|
|
ma420
|
117 |
32K |
4 |
11/07/24 |
11/07/24 |
ASX - By Stock
|
117
|
32K
|
4
|
|
ASX - By Stock
|
CU6 |
Re:
CU6 - Media and Industry News
|
|
ma420
|
630 |
267K |
48 |
11/07/24 |
11/07/24 |
ASX - By Stock
|
630
|
267K
|
48
|
|
ASX - By Stock
|
CU6 |
Re:
CU6 - Media and Industry News
|
|
ma420
|
630 |
267K |
21 |
11/07/24 |
11/07/24 |
ASX - By Stock
|
630
|
267K
|
21
|
|
ASX - By Stock
|
SNT |
Re:
SNT - Research & Valuation
|
|
ma420
|
24 |
6.2K |
4 |
10/07/24 |
10/07/24 |
ASX - By Stock
|
24
|
6.2K
|
4
|
|
ASX - By Stock
|
SNT |
Re:
SNT - General Discussions
|
|
ma420
|
117 |
32K |
6 |
10/07/24 |
10/07/24 |
ASX - By Stock
|
117
|
32K
|
6
|
|
ASX - By Stock
|
SNT |
SNT - Research & Valuation
|
|
ma420
|
24 |
6.2K |
6 |
10/07/24 |
10/07/24 |
ASX - By Stock
|
24
|
6.2K
|
6
|
|
ASX - By Stock
|
RAC |
Re:
Q. Bisantrene is not new. How can RAC monetise if it is out of patent?
|
|
ma420
|
391 |
86K |
12 |
10/07/24 |
10/07/24 |
ASX - By Stock
|
391
|
86K
|
12
|
|
ASX - By Stock
|
SNT |
Re:
SNT - General Discussions
|
|
ma420
|
117 |
32K |
6 |
10/07/24 |
10/07/24 |
ASX - By Stock
|
117
|
32K
|
6
|
|
ASX - By Stock
|
SNT |
Re:
SNT - General Discussions
|
|
ma420
|
117 |
32K |
7 |
10/07/24 |
10/07/24 |
ASX - By Stock
|
117
|
32K
|
7
|
|
ASX - By Stock
|
SNT |
Re:
SNT - General Discussions
|
|
ma420
|
117 |
32K |
8 |
10/07/24 |
10/07/24 |
ASX - By Stock
|
117
|
32K
|
8
|
|
ASX - By Stock
|
SNT |
Re:
SNT - General Discussions
|
|
ma420
|
117 |
32K |
7 |
10/07/24 |
10/07/24 |
ASX - By Stock
|
117
|
32K
|
7
|
|
ASX - By Stock
|
SNT |
Re:
SNT - General Discussions
|
|
ma420
|
117 |
32K |
10 |
10/07/24 |
10/07/24 |
ASX - By Stock
|
117
|
32K
|
10
|
|
ASX - By Stock
|
SNT |
Re:
SNT - General Discussions
|
|
ma420
|
117 |
32K |
6 |
10/07/24 |
10/07/24 |
ASX - By Stock
|
117
|
32K
|
6
|
|
ASX - By Stock
|
SNT |
Re:
SNT - General Discussions
|
|
ma420
|
117 |
32K |
16 |
10/07/24 |
10/07/24 |
ASX - By Stock
|
117
|
32K
|
16
|
|
ASX - By Stock
|
SNT |
Re:
SNT - General Discussions
|
|
ma420
|
117 |
32K |
5 |
10/07/24 |
10/07/24 |
ASX - By Stock
|
117
|
32K
|
5
|
|
ASX - By Stock
|
SNT |
Re:
SNT - General Discussions
|
|
ma420
|
117 |
32K |
6 |
10/07/24 |
10/07/24 |
ASX - By Stock
|
117
|
32K
|
6
|
|
ASX - By Stock
|
COV |
Re:
Ann: COV Ovarian Cancer Blood Test Outperforms Clinical Benchmark
|
|
ma420
|
62 |
28K |
0 |
10/07/24 |
10/07/24 |
ASX - By Stock
|
62
|
28K
|
0
|
|
ASX - By Stock
|
SNT |
Re:
SNT - General Discussions
|
|
ma420
|
117 |
32K |
5 |
10/07/24 |
10/07/24 |
ASX - By Stock
|
117
|
32K
|
5
|
|
ASX - By Stock
|
SNT |
Re:
Ann: Investor presentation
|
|
ma420
|
43 |
11K |
4 |
10/07/24 |
10/07/24 |
ASX - By Stock
|
43
|
11K
|
4
|
|
ASX - By Stock
|
SNT |
Re:
SNT - General Discussions
|
|
ma420
|
117 |
32K |
9 |
10/07/24 |
10/07/24 |
ASX - By Stock
|
117
|
32K
|
9
|
|
ASX - By Stock
|
COV |
Re:
Ann: COV Ovarian Cancer Blood Test Outperforms Clinical Benchmark
|
|
ma420
|
62 |
28K |
1 |
10/07/24 |
10/07/24 |
ASX - By Stock
|
62
|
28K
|
1
|
|
ASX - By Stock
|
SNT |
Re:
SNT - General Discussions
|
|
ma420
|
117 |
32K |
5 |
10/07/24 |
10/07/24 |
ASX - By Stock
|
117
|
32K
|
5
|
|
ASX - By Stock
|
NUZ Biotech |
Re:
Company Analysis - Morgans
|
|
ma420
|
19 |
8.7K |
18 |
10/07/24 |
10/07/24 |
ASX - By Stock
|
19
|
8.7K
|
18
|
|
ASX - By Stock
|
RAC |
Re:
Q. Bisantrene is not new. How can RAC monetise if it is out of patent?
|
|
ma420
|
391 |
86K |
14 |
09/07/24 |
09/07/24 |
ASX - By Stock
|
391
|
86K
|
14
|
|
ASX - By Stock
|
NUZ Biotech |
Re:
Company Analysis - Morgans
|
|
ma420
|
19 |
8.7K |
4 |
09/07/24 |
09/07/24 |
ASX - By Stock
|
19
|
8.7K
|
4
|
|
ASX - By Stock
|
CVB |
Re:
Ann: Sales Update for Q4 FY2024
|
|
ma420
|
23 |
8.7K |
4 |
09/07/24 |
09/07/24 |
ASX - By Stock
|
23
|
8.7K
|
4
|
|
ASX - By Stock
|
CVB |
Re:
Ann: Sales Update for Q4 FY2024
|
|
ma420
|
23 |
8.7K |
1 |
09/07/24 |
09/07/24 |
ASX - By Stock
|
23
|
8.7K
|
1
|
|
ASX - By Stock
|
SNT |
Re:
SNT - General Discussions
|
|
ma420
|
117 |
32K |
10 |
09/07/24 |
09/07/24 |
ASX - By Stock
|
117
|
32K
|
10
|
|
ASX - By Stock
|
SNT |
Re:
SNT - General Discussions
|
|
ma420
|
117 |
32K |
6 |
09/07/24 |
09/07/24 |
ASX - By Stock
|
117
|
32K
|
6
|
|
ASX - By Stock
|
RAC |
Re:
Q. Bisantrene is not new. How can RAC monetise if it is out of patent?
|
|
ma420
|
391 |
86K |
16 |
09/07/24 |
09/07/24 |
ASX - By Stock
|
391
|
86K
|
16
|
|
ASX - By Stock
|
CVB |
Re:
Ann: Sales Update for Q4 FY2024
|
|
ma420
|
23 |
8.7K |
0 |
09/07/24 |
09/07/24 |
ASX - By Stock
|
23
|
8.7K
|
0
|
|
ASX - By Stock
|
NUZ |
Re:
Ann: Investor Briefings & Webinar Notice
|
|
ma420
|
81 |
24K |
13 |
09/07/24 |
09/07/24 |
ASX - By Stock
|
81
|
24K
|
13
|
|
ASX - By Stock
|
SNT |
Re:
SNT - General Discussions
|
|
ma420
|
117 |
32K |
4 |
08/07/24 |
08/07/24 |
ASX - By Stock
|
117
|
32K
|
4
|
|
ASX - By Stock
|
SNT |
Re:
SNT - General Discussions
|
|
ma420
|
117 |
32K |
5 |
08/07/24 |
08/07/24 |
ASX - By Stock
|
117
|
32K
|
5
|
|
ASX - By Stock
|
SNT |
Re:
SNT - General Discussions
|
|
ma420
|
117 |
32K |
1 |
08/07/24 |
08/07/24 |
ASX - By Stock
|
117
|
32K
|
1
|
|